Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study

The Lancet Infectious Diseases

Volumn 16, Issue 3, 2016, Pages 311-320

  De Santis, Olga ^a   Audran, Régine ^b   Pothin, Emilie ^c   Warpelin Decrausaz, Loane ^b   Vallotton, Laure ^b   Wuerzner, Grégoire ^b   Cochet, Camille ^a   Estoppey, Daniel ^a   Steiner Monard, Viviane ^b   Lonchampt, Sophie ^a   Thierry, Anne Christine ^b   Mayor, Carole ^b   Bailer, Robert T ^d   Mbaya, Olivier Tshiani ^d   Zhou, Yan ^d   Ploquin, Aurélie ^d   Sullivan, Nancy J ^d   Graham, Barney S ^d   Roman, François ^e   De Ryck, Iris ^e   Ballou, W Ripley ^e   Kieny, Marie Paule ^f   Moorthy, Vasee ^f   Spertini, François ^b   Genton, Blaise ^a,b,c   more..

^a POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e GSK   (Belgium)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; CHIMPANZEE ADENOVIRUS TYPE 3 VECTOR; EBOLA VACCINE; EBOLA ZAIRE VACCINE; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; DNA VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILL; CLINICAL DEVELOPMENT PLAN; CONJUNCTIVITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INTENTION TO TREAT ANALYSIS; LYMPHADENOPATHY; MALAISE; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SWEATING; SWITZERLAND; ADENOVIRIDAE; BLOOD; CHEMICALLY INDUCED; CLASSIFICATION; CLINICAL TRIAL; DOSE RESPONSE; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MIDDLE AGED; SOLDIER; VIROLOGY; YOUNG ADULT;

ADENOVIRIDAE; ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EBOLA VACCINES; EBOLAVIRUS; FEMALE; FEVER; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MILITARY PERSONNEL; VACCINES, DNA; YOUNG ADULT;

EID: 84959245846     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00486-7     Document Type: Article

References (25)

1. Ebola situation report-30 September 2015 WHO, (accessed Oct 31, 2015). http://apps.who.int/ebola/current-situation/ebola-situation-report-30-september-2015.
2. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014, 20:1126-1129.
3. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29:304-313.
4. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine-preliminary report. N Engl J Med 2014, 373:776.
5. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe-preliminary report. N Engl J Med 2015, published online April 1. 10.1056/NEJMoa1502924.
6. Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against Ebolavirus challenge. J Virol 2011, 85:4222-4233.
7. Zhu F-C, Hou L-H, Li J-X, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015, 385:2272-2279.
8. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015, 386:857-866.
9. Krause PR Interim results from a phase 3 Ebola vaccine study in Guinea. Lancet 2015, 386:831-833.
10. Colloca S, Folgori A, Ammendola V, et al. Generation and screening of a large collection of novel simian adenovirus allows the identification of vaccine vectors inducing potent cellular immunity in humans. Sci Transl Med 2012, 4:115ra2.
11. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13:1267-1277.
12. Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 2015, 211:549-557.
13. Sullivan NJ, Sanchez A, Rollin PE, Yang Z, Nabel GJ Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408:605-609.
14. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424:681-684.
15. Rampling T, Ewer K, Bowyer G, et al. A monovalent chimpanzee adenovirus Ebola vaccine-preliminary report. N Engl J Med 2015, published online Jan 28. 10.1056/NEJMoa1411627.
16. O'Hara GA, Duncan CJA, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205:772-781.
17. Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2015, published online Nov 3. http://dx.doi.org/10.1016/S1473-3099(15)00362-X.
18. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012, 4:115ra1.
19. Sheehy SH, Duncan CJA, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 2012, 7:e31208.
20. Engerix®-B 20/Engerix®-B 10 Compendium Suiss des Mídicaments, (accessed April 15, 2015). http://compendium.ch/mpro/mnr/2546/html/fr.
21. Boostrix Compendium Suisse des Mídicaments, (accessed April 15, 2015). http://compendium.ch/mpro/mnr/9423/html/fr.
22. Priorix® Compendium Suisse des Mídicaments, (accessed April 15, 2015). http://compendium.ch/mpro/mnr/8773/html/fr.
23. Tetanol® pur Compendium Suisse des Mídicaments, (accessed April 15, 2015). http://compendium.ch/mpro/mnr/15386/html/fr.
24. Vaccines and Immunizations. Possible side-effects from vaccines Centers for Disease Control and Prevention, (accessed April 13, 2015). http://www.cdc.gov/vaccines/vac-gen/side-effects.htm.
25. Huttner A, Dayer J-A, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015, 15:1156-1166.